[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369151-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369151-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","clinical-activity-of-mitogen-activated-protein-kinase-inhibitors-in-patients-with-map2k1-mek1-mutated-metastatic-cancers","Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic Cancers","","MAP2K1/MEK1 mutations can act as actionable cancer drivers, yet the clinical effectiveness of MAPK pathway inhibitors for MAP2K1-mutant tumors is not well established. A systematic review and meta-analysis assessed genomic and clinical patterns across published patient reports and AACR GENIE data. Primary focus was progression-free survival, with secondary endpoints including ORR, DOR, and overall survival. Results support class 2 MAP2K1 mutations as a potentially distinct subgroup with greater benefit from MAPKi.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/clinical-activity-of-mitogen-activated-protein-kinase-inhibitors-in-patients-with-map2k1-mek1-mutated-metastatic-cancers/369151/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/clinical-activity-of-mitogen-activated-protein-kinase-inhibitors-in-patients-with-map2k1-mek1-mutated-metastatic-cancers/369151.png","ImageObject",300,407,{"name":42,"@type":43},"Eliana","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are MAP2K1/MEK1 mutations considered potentially actionable drivers in cancer?","Question",{"text":63,"@type":64},"MAP2K1/MEK1 mutations are recurrent oncogenic alterations within the MAPK pathway, and different mutation classes imply distinct signaling dependencies that may influence response to MAPK pathway inhibitors.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was clinical activity of MAPK pathway inhibitors evaluated in MAP2K1-mutant tumors?",{"text":68,"@type":64},"The analysis combined AACR GENIE genomic data with a systematic review and meta-analysis of published patient reports where individuals with MAP2K1-mutant cancers received MAPK inhibitors. Progression-free survival was the primary endpoint, with ORR, DOR, and overall survival as secondary endpoints.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the results show about outcomes by MAP2K1 mutation class?",{"text":72,"@type":64},"Across the meta-analysis, ORR was 28% and median PFS was 3.9 months, with ORR not differing by mutation class or cancer type. However, class 2 mutations were associated with longer PFS and duration of response compared with class 1, class 3, or unclassified mutations.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369151,1790826707,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","Review Articles  \nClinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic Cancers  \nMatthew Dankner, MD, PhD1,2,3 ; Emmanuelle Rousselle, BSc2,4 ; Sarah Petrecca, MSc1 ; François Fabi, MD, PhD1  ;  \nAlexander Nowakowski, BSc1,3 ; Anna-Maria Lazaratos, BSc3 ; Charles Vincent Rajadurai, MD, PhD1,2 ; Andrew J.B. Stein, MD1; David Bian, MD1; Peter Tai, DEC1; Alicia Belaiche, DEC1 ; Meredith Li, MD1,2; Andrea Quaiattini, MA, MLIS5 ; Nicola Normanno, MD6 ; Maria Arcila, MD7; Arielle Elkrief, MD7,8 ; Douglas B. Johnson, MD9 ; Marc Ladanyi, MD7 ; and April A.N. Rose, MD, PhD1,2,4,10   \nDOI [https://doi.org/10.1200/PO.24.00199](https://doi.org/10.1200/PO.24.00199)  \n\n| ABSTRACT |  |\n| --- | --- |\n| PURPOSE | MAP2K1/MEK1 mutations are potentially actionable drivers in cancer. MAP2K1 mutations have been functionally classiﬁed into three groups according to their dependency on upstream RAS/RAF signaling. However, the clinical efﬁcacy of mitogen-activated protein kinase (MAPK) pathway inhibitors (MAPKi) for MAP2K1-mutant tumors is not well deﬁned. We sought to characterize the genomic and clinical landscape of MAP2K1 mutant tumors to evaluate the relationship between MAP2K1 mutation class and clinical activity of MAPKi. |\n| METHODS | We interrogated American Association for Cancer Research (AACR) GENIE (v13) to analyze solid tumors with MAP2K1 mutations. We performed a systematic review and meta-analysis of published reports of patients with MAP2K1-mutant cancers treated with MAPKi according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The primary end point was progression-free survival (PFS), and secondary end points were overall treatment response rate (ORR), duration of response (DOR), and overall survival. |\n| RESULTS | In the AACR GENIE data set, class 2 MAP2K1 mutations (63%) were more prevalent than class 1 (24%) and class 3 (13%) mutations (P \u003C .0001) . Cooccurring MAPK pathway-activating mutations were more likely to occur in class 1 versus class 2 or 3 MAP2K1-mutant tumors (P \u003C .0001) . Our systematic meta-analysis of the literature identiﬁed 46 patients with MAP2K1-mutant tumors who received MAPKi. In these patients, ORR was 28% and median PFS was 3.9 months. ORR did not differ according to MAP2K1 mutation class or cancer type. However, patients with class 2 mutations experienced longer PFS (5.0 months) and DOR (23.8 months) compared with patients with class 1, 3, or unclassiﬁed MAP2K1 mutations (PFS 3 . 5 months, P 5 . 04; DOR 4 .2 months, P 5 . 02) . |\n| CONCLUSION | Patients with class 2 MAP2K1 mutations represent a novel subgroup that may derive beneﬁt from MAPKi. Prospective clinical studies with novel MAPKi regimens are warranted in these patients. |\n\nACCOMPANYING CONTENT  \n Appendix  \n Data Sharing Statement  \n Data Supplement  \nAccepted October 31, 2024 Published January 27, 2025  \nJCO Precis Oncol 9:e2400199 © 2025 by American Society of Clinical Oncology  \nCreative Commons Attribution Non-Commercial No Derivatives 4.0 License  \nINTRODUCTION  \nMAP2K1 (MEK1) is a kinase and a key constituent of the mitogen-activated protein kinase (MAPK) pathway which drives cellular proliferation and survival.1-3 It is a recurrently mutated oncogene in human cancers, particularly Langerhans cell histiocytosis, melanoma, colorectal cancer, and non–small cell lung adenocarcinoma.4-8  \nSeveral hotspot driver mutations in MAP2K1 have been deﬁned genetically and biochemically. These mutations were identiﬁed in treatment-nave tumors as well as in those resistant to MAPK targeted therapies.7,9-15 A number of MAP2K1 mutations have been demonstrated tobe oncogenic via their ability to transform noncancerous cells, or by increasing the phosphorylation of downstream ERK.10,11 ,13,16-28 In 2018, Gao et al13 proposed a classiﬁcation system for  \n[ascopubs.org/journal/po](ascopubs.org/journal/po | 1)[ |](ascopubs.org/journal/po | 1)[ 1](ascopubs.org/journa","cbCaiaXS51TcHxaB","https://ap.wps.com/l/cbCaiaXS51TcHxaB","pdf",1206682,18,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction\n## MAP2K1 role in the MAPK pathway\n## MAP2K1 mutation classes and biological rationale\n## Need for clinical evidence and treatment decision guidance","[{\"question\":\"Why are MAP2K1/MEK1 mutations considered potentially actionable drivers in cancer?\",\"answer\":\"MAP2K1/MEK1 mutations are recurrent oncogenic alterations within the MAPK pathway, and different mutation classes imply distinct signaling dependencies that may influence response to MAPK pathway inhibitors.\"},{\"question\":\"How was clinical activity of MAPK pathway inhibitors evaluated in MAP2K1-mutant tumors?\",\"answer\":\"The analysis combined AACR GENIE genomic data with a systematic review and meta-analysis of published patient reports where individuals with MAP2K1-mutant cancers received MAPK inhibitors. Progression-free survival was the primary endpoint, with ORR, DOR, and overall survival as secondary endpoints.\"},{\"question\":\"What did the results show about outcomes by MAP2K1 mutation class?\",\"answer\":\"Across the meta-analysis, ORR was 28% and median PFS was 3.9 months, with ORR not differing by mutation class or cancer type. However, class 2 mutations were associated with longer PFS and duration of response compared with class 1, class 3, or unclassified mutations.\"}]","Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic Cancers | PDF",1790181010,45,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/848bf9aee685fb4634d7378249c9af5f.webp",983,1315,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/224a4b5c714e1935492cc475e1ef407e.webp",982,1314,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b0cfe5821c15c61b8ecf435925bedaf6.webp",981,1312,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/43f290897a22dddd852d832ba1094758.webp",980,1311]